POXVIRUS IMMUNITY AND DNA/MVA HIV VACCINES

痘病毒免疫和 DNA/MVA HIV 疫苗

• 批准号: 7349212
• 负责人: Rama Rao Amara
• 金额: $ 5.97万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-06-09 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349212
• 关键词: AIDS vaccines; DNA; Macaca; Poxviridae; cellular immunity; immunity

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. During this period, we evaluated the vaccinia-specific cellular immunity elicited by the DNA/MVA HIV vaccine and compare with vaccinia-specific immunity elicited by the current smallpox vaccine DryVax?. Macaques were primed with 0.6 mg of DNA/HIV on week 0 and boosted with 1x108 pfu of MVA/HIV 48 on weeks 8 and 32. Ten more macaques were primed with DryVax? using standard human dose by scarification. Vaccinia-specific T cells were measured at 1 and 8 weeks following each immunization. Following the second MVA boost, both CD4 and CD8 responses underwent a rapid expansion. At this time, the magnitude of vaccinia-specific CD4 cells ranged from 0.02% to 0.14% of total CD4 cells and the magnitude of vaccinia-specific CD8 cells ranged from 0.06% to 2.1% of total CD8 cells. By 8 weeks post the second MVA boost, the CD4 responses were generally stable and the CD8 responses contracted 5 fold. These responses were maintained at this level even at two years post the second MVA boost. A single dose inoculation of DryVax? elicited a robust CD4 and CD8 response. At peak vaccine response, the vaccinia-specific CD4 response raised by DryVax? vaccine ranged from 0.09% to 1.23% with a geometric mean frequency of 0.44% of total CD4 cells. The vaccinia-specific CD8 response raised by the DNA/MVA vaccine was about 5 fold lower than the vaccinia-specific CD8 response raised by DryVax?. Our results demonstrate that the DNA/MVA-HIV vaccines elicit cellular immunity that is comparable to that of elicited by the DryVax? vaccinations in macaques and strongly suggest that this HIV vaccine may also serve as a vaccine for smallpox.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。在此期间，我们评估了DNA/MVA HIV疫苗引起的疫苗特异性细胞免疫，并与当前天花疫苗Dryvax？引起的疫苗特异性免疫相比。猕猴在第0周用0.6 mg的DNA/HIV启动，并在第8和32周用MVA/HIV 48的1x108 PFU提升。另外十个猕猴还用Dryvax启动？使用标准的人剂量通过疤痕。 每次免疫后1和8周测量疫苗特异性T细胞。在第二个MVA增强后，CD4和CD8响应都经历了快速扩展。目前，疫苗特异性CD4细胞的大小范围为0.02％至总CD4细胞的0.14％，疫苗特异性CD8细胞的幅度范围从0.06％到总CD8细胞的2.1％不等。第二个MVA提升后8周，CD4响应通常稳定，CD8响应收缩了5倍。即使在第二次MVA提升后的两年后，这些响应仍在此级别上保持。 Dryvax的一次剂量接种？引起了强大的CD4和CD8响应。在峰值疫苗反应时，Dryvax提出的疫苗特异性CD4反应？疫苗范围从0.09％到1.23％，几何平均频率为总CD4细胞的0.44％。由DNA/MVA疫苗提出的离子特异性CD8响应比Dryvax提出的疫苗特异性CD8响应低约5倍。 我们的结果表明，DNA/MVA-HIV疫苗会引起与Dryvax引起的可比的细胞免疫？猕猴中的疫苗接种，并强烈表明这种HIV疫苗也可以用作天花的疫苗。